DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: MAXALT

Summary for Tradename: MAXALT

Patents:1
Applicants:1
NDAs:2
Suppliers: see list6
drug
patent expirations by year for
 MAXALT

Clinical Trials for: MAXALT

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
Status: Completed Condition: Migraine Disorders

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops
Status: Recruiting Condition: Chronic Post-traumatic Headache

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)
Status: Completed Condition: Migraine Disorders

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
Status: Completed Condition: Migraine, Acute

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
Status: Completed Condition: Migraine Headache

Two Rizatriptan Prescribing Portions for Treatment of Migraine
Status: Completed Condition: Migraine

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
Status: Completed Condition: Migraine With Aura; Migraine Without Aura

A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Status: Completed Condition: Acute Migraine With or Without Aura in Adolescents

Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.
Status: Completed Condition: Migraine

A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
Status: Completed Condition: Migraine

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864Jun 29, 1998RXNo<disabled><disabled>
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864Jun 29, 1998RXNo<disabled><disabled>
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864Jun 29, 1998RXYes<disabled><disabled>
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864Jun 29, 1998RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MAXALT

Drugname Dosage Strength RLD Submissiondate
rizatriptan benzoateOrally Disintegrating Tablets5 mg and 10 mgMaxalt-MLT2/17/2006
rizatriptan benzoateTablets5 mg and 10 mgMaxalt9/2/2004

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc